Bacillus anthracis protective antigen nucleic acid sequences
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsStephen H. Leppla, Yogendra Singh, Kurt Klimpel, Rachel Schneerson, John B. Robbins
Life of this patent
Estimating the term…
Abstract
The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.
Claims8
An isolated nucleic acid molecule encoding a modified Bacillus anthracis (B. anthracis) protective antigen, wherein the antigen comprises a B. anthracis protective antigen modified such that the amino acid sequence RKKR167 (SEQ ID NO:
- 14) has been changed to SNKE167 (SEQ ID NO:
- 15), the two phenylalanines at positions 313-314 are deleted, and the glutamic acid at position 308 is substituted with aspartic acid.
Dependencies are inferred from the claim text.